- Home
- CODA vs MSLE Comparison
CODA vs MSLE Comparison
Compare CODA & MSLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CODA | MSLE |
|---|---|---|
| Founded | 1994 | N/A |
| Country | United States | Canada |
| Employees | N/A | 17 |
| Industry | Industrial Machinery/Components | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.4M | 146.9M |
| IPO Year | 2007 | N/A |
Fundamental Metrics
Financial Performance| Metric | CODA | MSLE |
|---|---|---|
| Price | $11.16 | $5.75 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 96.5K | 27.5K |
| Earning Date | 06-15-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 15.62 | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $20,316,161.00 | N/A |
| Revenue This Year | $18.28 | N/A |
| Revenue Next Year | $12.62 | N/A |
| P/E Ratio | $148.75 | ★ N/A |
| Revenue Growth | ★ 4.98 | N/A |
| 52 Week Low | $7.01 | $5.50 |
| 52 Week High | $18.00 | $13.39 |
Technical Indicators
Market Signals| Indicator | CODA | MSLE |
|---|---|---|
| Relative Strength Index (RSI) | 40.22 | 37.65 |
| Support Level | $10.85 | $5.56 |
| Resistance Level | $12.24 | $8.59 |
| Average True Range (ATR) | 0.75 | 0.44 |
| MACD | -0.13 | -0.09 |
| Stochastic Oscillator | 0.00 | 7.10 |
Price Performance
Historical ComparisonAbout CODA Coda Octopus Group Inc.
Coda Octopus Group Inc develops underwater technologies and equipment for imaging, mapping defense, and survey applications. The company operates in three distinct business segments: the Marine Technology business, Acoustic Sensors and Material Business and the Defense Engineering Services Business. Its geographical segments are the Americas, Europe, Australia/Asia, and the Middle East/Africa. The majority of revenue is derived from the Products segment.
About MSLE Satellos Bioscience Inc. Common Stock
Satellos Bioscience Inc is a regenerative medicine company a biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease.